Cost-effectiveness of hepatitis B vaccination of prison inmates

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 312-321

  Pisu, Maria ^a,b   Meltzer, Martin Isaac ^a   Lyerla, Rob ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Center for Outcomes and Effectiveness Research and Education   (United States)

Author keywords

Cost effectiveness; Hepatitis; Prison

Indexed keywords

HEPATITIS B VACCINE;

ACUTE DISEASE; ARTICLE; CHRONIC LIVER DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; HEALTH CARE SYSTEM; HEPATITIS B; HEPATITIS B VIRUS; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; PRISON; RESOURCE ALLOCATION; VACCINATION; COMPUTER PROGRAM; COST BENEFIT ANALYSIS; DECISION TREE; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; IMMUNOLOGY; MALE; PREVENTIVE HEALTH SERVICE; PRISONER; RISK ASSESSMENT; STATISTICS; TREATMENT OUTCOME;

COST SAVINGS; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HEALTH CARE COSTS; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MALE; PREVENTIVE HEALTH SERVICES; PRISONERS; RISK ASSESSMENT; SOFTWARE; TREATMENT OUTCOME; VACCINATION;

EID: 0037073543     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00457-7     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP) on inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep 1982;31(24):317-22, 327-8.
2. Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP): Recommendations for protection against viral hepatitis. MMWR Morb Mortal Wkly Rep 1985;34(22):313-24, 329-35.
3. Update on adult immunization: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991;40(RR12):1-52.
4. Centers for Disease Control and Prevention. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991;40(RR-13):1-19.
5. Khan A, Goldstein S, Williams I, Bell B, Mast E. Opportunities for hepatitis B prevention in correctional facilities and sexually transmitted disease treatment settings [abstract]. In: Proceedings of the 10th International Symposium on Viral Hepatitis and Liver Disease. 9-13 April 2000, Atlanta: US International Medical Press; 2000. p. 21 [Abstract 37].
6. Center for Disease Control and Prevention. Risk behaviors for HIV transmission among intravenous-drug users not in drug treatment: United States, 1987-1989. MMWR Morb Mortal Wkly Rep 1990;39(16):273-76.
7. National Commission on Correctional Health Care. Standards for Health Services in Prisons. 2nd Ed. Chicago: National Commission on Correctional Health Care; November 1998.
8. Anda R.F., Perlman S.B., D'Alessio D.J., Davis J.P., Dodson V.N. Hepatitis B in Wisconsin male prisoners: considerations for serologic screening and vaccination. AM. J. Publ. Health. 75:1985;1182-1185.
9. Tucker R.M., Gaffey M.J., Fisch M.J., Kaiser D.L., Guerrant R.L., Normansell D.E. Seroepidemiology of hepatitis D (delta agent) and hepatitis B among Virginia state prisoners. Clin. Ther. 9(6):1987;622-628.
10. Ruiz JD, Mikanda J. Seroprevalence of HIV, Hepatitis B, Hepatitis C, and Risk Behaviors Among Inmates Entering the California Correctional System. California Department of Health Services, Office of AIDS, HIV/AIDS Epidemiology Branch; March 1996.
11. Beck A, Gillard D, Greenfeld L, et al. Survey of State Prison Inmates 1991. Report No. NCJ-136949. Bureau of Justice Statistics, US Department of Justice; March 1993, available at URL: http://www.ojp.usdoj.gov/bjs/abstract/sospi91.htm .
12. Decker M.D., Vaughn W.K., Brodie J.S., Hutcheson R.H. Jr., Schaffner W. Seroepidemiology of hepatitis B in Tennessee prisoners. J. Infect. Dis. 150:1984;450-459.
13. Hull H.F., Lyons L.H., Mann J.M., Hadler S.C., Steece R., Skeels M.R. Incidence of hepatitis B in the penitentiary of New Mexico. AM. J. Publ. Health. 75:1985;1213-1214.
14. Chiaramonte M., Trivello R., Renzulli G.et al. Hepatitis B virus infection in prisons: a seroepidemiological survey in prisoners and attending staff. J. Hyg. (Lond.). 89(1):1982;53-58.
15. Prefontaine R.G., Chaudhary R.K. Serepidemiologic study of hepatitis B and C viruses in Federal Correction Institutions in British Columbia. Can. Dis. Wkly. Rep. 16(52):1990;265-266.
16. Del Olmo J.A., Llovet F., Rodrigo J.M.et al. Prevalence of liver disease and infection by hepatitis B, delta virus, and human immunodeficiency virus in two Spanish penitentiaries. Med. Microbiol. Immunol. (Berl.). 179:1990;43-48.
17. Bayas J.M., Bruguera M., Martin V., Vidal J., Rodes J., Salleras L.Y. Hepatitis B vaccination in prisons: the Catalonian experience. Vaccine. 11:1993;1441-1444.
18. Butler T., Spencer J., Cui J., Vickery K., Zou J., Kaldor J. Seroprevalence of markers for hepatitis B, C, and G in male and female prisoners - NSW 1996. Aust. N. Z. J. Publ. Health. 23(4):1999;377-384.
19. Hurlen B., Jacobsen N., Hurlen P. Hepatitis B serum markers and oral health in a group of Norwegian male prisoners. Acta Odontol. Scand. 42(1):1984;53-58.
20. Crofts N., Stewart T., Hearne P., Ping X.Y., Breschkin A.M., Locarnini S.A. Spread of bloodborne viruses among Australian prison entrants. BMJ. 310:1995;285-288.
21. Butler T.G., Dolan K.A., Ferson M.J., McGuinness L.M., Brown P.R., Robertson P.W. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med. J. Aust. 166:1997;127-130.
22. Rotily M., Vernay-Vasse C., Bourliere M., Galinier-Pujol A., Rousseau S., Obadia Y. HBV and HIV screening, and hepatitis B immunization programme in the prison of Marseille, France. Int. J. STD AIDS. 8:1997;753-759.
23. Szmuness W., Stevens C., Harley E.et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 303:1980;833-841.
24. Hadler S.C., Francis D.P., Maynard J.E.et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 315:1986;209-214.
25. Decker M.D., Vaughn W.K., Brodie J.S., Hutcheson R.H. Jr., Schaffner W. The incidence of Hepatitis B in Tennessee prisoners. J. Infect. Dis. 152:1985;214-217.
26. Centers for Disease Control and Prevention. Hepatitis B Surveillance Report No. 56. Atlanta: Centers for Disease Control and Prevention; 1995. p. 36.
27. Glaser J.B., Greifinger R.B. Correctional health care: a public health opportunity. Ann. Intern. Med. 118:1993;139-145.
28. Barry M.A., Gleavy D., Herd K., Schwingl P.J., Werner B.G. Prevalence of markers for hepatitis B and hepatitis D in a municipal house of correction. Am. J. Publ. Health. 80:1990;471-473.
29. Beck AJ, Shipley BE. Recidivism of Prisoners Released in 1983. Report no.: NCJ 116261. Bureau of Justice Statistics, US Department of Justice; April 1989, available at URL: http://www.ojp.usdoj.gov/bjs/abstract/rpr83.htm.
30. Schmidt P, Witte AD. Predicting Recidivism Using Survival Models. NY: Springer; 1988.
31. Margolis H.S., Coleman P.J., Brown R.E., Mast E.E., Sheingold S.H., Arevalo J.A. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 274(15):1995;1201-1208.
32. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. NY: Oxford University Press; 1996.
33. Bureau of Justice Statistics. National Prisoner Statistics Data Series (NPS-1). Correctional populations in the United States, available at URL: http://wwwojp.usdoj.gov/bjs/pubalp2.htm.
34. Varghese B., Peterman P.A. Cost effectiveness of HIV counseling and testing in US prisons. J. Urban Health. 78(2):2001;304-312.
35. Jones T.F., Schaffner W. Miniature chest radiograph screening for tuberculosis in jails: a cost-effectiveness analysis. Am. J. Respir. Crit. Care. Med. 164:2001;77-81.
36. Centers for Disease Control and Prevention. Sensitivity of the test for antibody to hepatitis B surface antigen, United States. MMWR Morb Mortal Wkly Rep 1993;42(36):707-10.